Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.
| Revenue (TTM) | $6.64M |
| Gross Profit (TTM) | $6.47M |
| EBITDA | $-17.55M |
| Operating Margin | -372.60% |
| Return on Equity | -47.00% |
| Return on Assets | -32.50% |
| Revenue/Share (TTM) | $0.60 |
| Book Value | $2.16 |
| Price-to-Book | 2.20 |
| Price-to-Sales (TTM) | 12.88 |
| EV/Revenue | 113.99 |
| EV/EBITDA | 0.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 74.60% |
| Shares Outstanding | $18.13M |
| Float | $8.31B |
| % Insiders | 0.00% |
| % Institutions | 1.81% |
Volatility is currently contracting